Results 231 to 240 of about 298,780 (335)

Building a Robust Investigator‐Initiated Platform: The I‐CARE Experience

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Investigator‐initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I‐CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 countries for up to 6 years.
Julien Kirchgesner   +906 more
wiley   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo   +8 more
wiley   +1 more source

Practical parameter identifiability and handling of censored data with Bayesian inference in mathematical tumour models. [PDF]

open access: yesNPJ Syst Biol Appl
Porthiyas J   +5 more
europepmc   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi   +100 more
wiley   +1 more source

Model Calibration With Censored Data

open access: green, 2017
Fang Cao   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy